FDA career scientists are pushing back against expanding compounding pharmacy access to seven unproven peptides, citing insufficient safety and efficacy data. Meanwhile, the newly assembled advisory panel set to vote on the issue includes several members who run peptide clinics or businesses — raising conflict-of-interest concerns. The final decision is expected after the July 23–24 meeting.
FDA career scientists have posted briefing documents recommending against loosening restrictions on seven peptides — including BPC-157, TB-500, and emideltide — that compounding pharmacies want to produce for conditions ranging from ulcerative colitis to insomnia and obesity. Their conclusion: insufficient evidence on safety and efficacy in humans. This puts agency experts at odds with HHS Secretary Robert F. Kennedy Jr., a self-described "big fan" of peptides who has spoken publicly about using them for injuries.
Adding to the concern, the FDA released its roster for the July 23–24 Pharmacy Compounding Advisory Committee (PCAC) meeting, and critics say the composition raises questions about independence. At least seven of the new members run peptide clinics, sell peptide injections, or promote the substances online. Previous iterations of the same panel — drawn from Duke, Harvard, and Johns Hopkins — repeatedly voted against allowing peptide ingredients into compounded medications.
Key Takeaways:
Why it matters: The composition of this panel — and the political pressure surrounding it — could set a precedent for how advisory committees are assembled and how evidence standards are applied when there is top-down pressure from HHS leadership. The outcome will likely influence not just peptide policy, but the integrity of the FDA's advisory process more broadly.
